Opca Bolnica Dr. Ivo Pedisic Sisak
- Address
- Ulica Josipa Jurja Strossmayera 59, 44000 Sisak, Croatia
Opca Bolnica Dr. Ivo Pedisic Sisak - Respiratory Disease Research Center
Opca Bolnica Dr. Ivo Pedisic Sisak is a specialized clinical research facility focused on advancing treatments for chronic respiratory conditions. The center demonstrates expertise in conducting Phase 2 and advanced clinical trials evaluating novel therapeutic approaches for patients with obstructive airway diseases.
- Chronic Obstructive Pulmonary Disease (COPD) management and exacerbation prevention studies
- Moderate-to-severe uncontrolled asthma treatment optimization
- Novel add-on therapies to existing maintenance respiratory treatments
The research center specializes in evaluating innovative pharmacological interventions, including phosphodiesterase-4 (PDE4) inhibitors and leukotriene pathway modulators, as add-on treatments to standard care regimens. Their clinical trial portfolio includes long-term efficacy studies assessing exacerbation reduction in COPD patients on triple therapy, as well as trials investigating new oral therapies for patients with difficult-to-control asthma who remain symptomatic despite conventional treatment approaches.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 10 by active trials.
No sponsors linked to active trials.
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
No repeated partnerships found.
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 60 other sites in Croatia
Therapeutic Area Benchmark — Croatia
Select a therapeutic area to compare against other sites in Croatia.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Croatia
Market Share
Country: Croatia
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Opca Bolnica Dr. Ivo Pedisic Sisak
lock Showing 1 of 2 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| Efficacy and Safety Evaluation of Atuliflapon in Adults with Moderate-to-Severe Uncontrolled Asthma: A Phase 2a Randomized, Double-Blind, Placebo-Controlled Trial | AstraZeneca AB | Phase II | Not Recruiting | Apr 2023 | Dec 2025 |
IMP list
lock Showing 1 of 4 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Atuliflapon | 1 | Unknown | 2023-04-12 | 2023-04-12 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.